Sprott Focused Global Dividend Class

October 2017 Commentary

Year-to-date to October 31, the Sprott Focused Global Dividend Class generated a total return of 13.2% compared to the MSCI World Index, which generated a total return of 13.6%.

Returns in the month of October were excellent, with the Fund generating a total return of 4.9% while the benchmark generated a total return of 5.4%. Although slightly behind the index over the month, given the significant outperformance of the technology sector, investors should be generally pleased to have kept pace in a dividend-focused, broadly-diversified fund.

Returns in October were also positively impacted by a weakening CAD versus the USD. As we had suggested in prior commentary, modelling indicated that some of the recent Canadian dollar strength was unwarranted and was likely to reverse, which played out in October to our benefit.

Top contributors to the year-to-date performance of the Sprott Focused Global Dividend Class included Mastercard (+140 bps), Visa (+131 bps) and Alphabet (+120 bps). Top detractors year-to-date included Macquarie Infrastructure (-49 bps), Disney (-30 bps) and Nextdc (-26 bps). Note that we have eliminated all three of these securities due to stock-specific factors that led to the disappointing performance.

Looking to increase our European exposure in the portfolio, we recently added Siemens AG, a global leader in factory automation, electrification and digitalization. We built our position during a period of elevated concern regarding the outlook for the Company’s Power & Gas and Renewable Energy segments, where orders have admittedly slowed. However management is in the midst of realigning the portfolio, fixing or divesting underperforming businesses (anything with a profit margin below 6%) and refocusing on profitable growth, which should drive better share price performance going forward.

In terms of catalysts, we are currently awaiting the initial public offering of Healthineers, Siemens’ healthcare division offering medical imaging and laboratory diagnostics, in the first half of calendar 2018. This segment is not insignificant, generating €13.8 billion in revenue in fiscal 2017 at an 18.1% profit margin. With healthcare companies trading at elevated multiples compared to multi-industrials, initial estimates have valued the Healthineers business at up to €40 billion euros, or just over 30% of Siemens’ enterprise value today.

At a forward price to earnings multiple of only 16x (US multi-industrials are currently trading at 20x forward earnings expectations) and a forward enterprise value to EBITDA multiple of only 11x (US multi-industrials are currently trading at 14x forward EBITDA expectations), we would expect an uplift once the Healthineers IPO is completed. In the meantime, the 2.9% dividend yield meets our income needs.

The Sprott Focused Global Dividend Class was concentrated in 28 positions as at October 31, 2017 with the top 10 holdings accounting for approximately 42% of the fund. Over the past year, 20 out of our 28 holdings have announced a dividend increase, with an average hike of 19.2%. We will continue to apply a disciplined investment process, balancing various quality and valuation metrics, in an effort to generate solid risk-adjusted returns.

Jeffrey Sayer, CFA



1 All returns and fund details are a) based on Series F shares; b) net of fees; c) annualized if period is greater than one year; d) as at October 31, 2017; e) 2015 annual returns are from 11/25/15 to 12/31/15. The index is S&P GLOBAL 1200 TR (CAD) and is computed by Ninepoint Partners LP based on publicly available index information.

The Fund is generally exposed to the following risks. See the prospectus of the Fund for a description of these risks: ADR risk; Capital depletion risk; Capital gains risk; Class risk; Credit risk; Currency risk; Cybersecurity risk; Derivatives risk; Exchange traded funds risk; Foreign investment risk; Inflation risk; Interest rate risk; Liquidity risk; Market risk; Securities lending, Repurchase and reverse repurchase transactions risk; Series risk; Short selling risk; Specific issuer risk; Tax risk.

Ninepoint Partners LP is the investment manager to the Ninepoint Funds (collectively, the “Funds”). Commissions, trailing commissions, management fees, performance fees (if any), and other expenses all may be associated with investing in the Funds. Please read the prospectus carefully before investing. The indicated rate of return for series F shares of the Fund for the period ended October 31, 2017 is based on the historical annual compounded total return including changes in share value and reinvestment of all distributions and does not take into account sales, redemption, distribution or optional charges or income taxes payable by any unitholder that would have reduced returns. Mutual funds are not guaranteed, their values change frequently and past performance may not be repeated. The information contained herein does not constitute an offer or solicitation by anyone in the United States or in any other jurisdiction in which such an offer or solicitation is not authorized or to any person to whom it is unlawful to make such an offer or solicitation. Prospective investors who are not resident in Canada should contact their financial advisor to determine whether securities of the Fund may be lawfully sold in their jurisdiction.

The opinions, estimates and projections (“information”) contained within this report are solely those of Ninepoint Partners LP and are subject to change without notice. Ninepoint Partners makes every effort to ensure that the information has been derived from sources believed to be reliable and accurate. However, Ninepoint Partners assumes no responsibility for any losses or damages, whether direct or indirect, which arise out of the use of this information. Ninepoint Partners is not under any obligation to update or keep current the information contained herein. The information should not be regarded by recipients as a substitute for the exercise of their own judgment. Please contact your own personal advisor on your particular circumstances. Views expressed regarding a particular company, security, industry or market sector should not be considered an indication of trading intent of any investment funds managed by Ninepoint Partners LP. Any reference to a particular company is for illustrative purposes only and should not to be considered as investment advice or a recommendation to buy or sell nor should it be considered as an indication of how the portfolio of any investment fund managed by Ninepoint Partners LP is or will be invested. Ninepoint Partners LP and/ or its affiliates may collectively beneficially own/control 1% or more of any class of the equity securities of the issuers mentioned in this report. Ninepoint Partners LP and/or its affiliates may hold short position in any class of the equity securities of the issuers mentioned in this report. During the preceding 12 months, Ninepoint Partners LP and/or its affiliates may have received remuneration other than normal course investment advisory or trade execution services from the issuers mentioned in this report.

The information provided is general in nature and is provided with the understanding that it may not be relied upon as, nor considered to be, the rendering or tax, legal, accounting or professional advice. Readers should consult with their own accountants and/or lawyers for advice on the specific circumstances before taking any action.

Ninepoint Partners LP: Toll Free: 1.866.299.9906. DEALER SERVICES: CIBC Mellon GSSC Record Keeping Services: Toll Free: 1.877.358.0540

Related Funds

Historical Commentary